Benjamin Morin shared a post on LinkedIn about a paper by Kwang-Soo Kim et al. published in Neuro-Oncology.
Authors: Kwang-Soo Kim, Karl Habashy, Andrew Gould, Catalina Lee-Chang, Adam Sonabend et al.
“Great team work demonstrating that FC-enhanced anti-CTLA-4 together with anti-PD-1 and doxorubicin, when delivered with concomitant ultrasound-mediated blood-brain barrier opening, promotes robust anti-tumor effects in resistant murine gliomas!
These data are the basis for the ongoing collaborative clinical trial ((NCT05864534).”
Source: Benjamin Morin/LinkedIn
Benjamin Morin is the Senior Director at Agenus, where he focuses on preclinical portfolio strategy and development, overseeing target identification to IND. He previously served as a Postdoctoral Fellow at Harvard Medical School.